N-acetylcysteine and contrast-induced nephropathy in primary angioplasty

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Patients with acute myocardial infarction undergoing primary angioplasty are at high risk for contrast-medium-induced nephropathy because of hemodynamic instability, the need for a high volume of contrast medium, and the lack of effective prophylaxis. We investigated the antioxidant N-acetylcysteine for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty. METHODS: We randomly assigned 354 consecutive patients undergoing primary angioplasty to one of three groups: 116 patients were assigned to a standard dose of N-acetylcysteine (a 600-mg intravenous bolus before primary angioplasty and 600 mg orally twice daily for the 48 hours after angioplasty), 119 patients to a double dose of N-acetylcysteine (a 1200-mg intravenous bolus and 1200 mg orally twice daily for the 48 hours after intervention), and 119 patients to placebo. RESULTS: The serum creatinine concentration increased 25 percent or more from baseline after primary angioplasty in 39 of the control patients (33 percent), 17 of the patients receiving standard-dose N-acetylcysteine (15 percent), and 10 patients receiving high-dose N-acetylcysteine (8 percent, P

Original languageEnglish
Pages (from-to)2773-2782
Number of pages10
JournalNew England Journal of Medicine
Volume354
Issue number26
DOIs
Publication statusPublished - Jun 29 2006

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'N-acetylcysteine and contrast-induced nephropathy in primary angioplasty'. Together they form a unique fingerprint.

  • Cite this